Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
We began building a position in Journey Medical in February. Journey is a...
— Andrew Summers
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Journey Medical
Journey Medical represents a compelling specialty pharmaceutical play backed by its recent FDA approval of Emrosi for treating Rosacea. Emrosi has shown...
Journey Medical Corporation, despite a challenging year-to-date performance, shows promising signs of recovery and growth. The company's Q2...
More institutional theses from Summers Value Fund
UFP Technologies continued its outstanding run in 2024, bolstered by acquisitions and a growing relationship with Intuitive Surgical. The manager trimmed...
Electromed delivered record-breaking sales, earnings, and cash generation under a new leadership team, causing the stock to soar by 176%. The company's SmartVest...
The fund initiated a position in Indivior at an attractive valuation of 10x expected earnings after a guidance cut caused a temporary stock drop. The manager expects...